Table 4.
Hazard Analysis for 7-year Follow-up
Unadjusted | Multivariable-adjusteda | |||||
---|---|---|---|---|---|---|
| ||||||
Hazards Ratio | 95% CI | p-value | Hazards Ratio | 95% CI | p-value | |
LDL Cholesterol | ||||||
| ||||||
175+ mg/dL | reference | reference | ||||
153-174 mg/dL | 1.11 | 0.91-1.31 | 0.25 | 1.19 | 0.99-1.43 | 0.06 |
134-152 mg/dL | 1.08 | 0.91-1.27 | 0.43 | 1.17 | 0.97-1.40 | 0.09 |
114-133 mg/dL | 1.07 | 0.91-1.27 | 0.42 | 1.10 | 0.91-1.32 | 0.32 |
<114 mg/dL | 1.27 | 1.08-1.49 | 0.0039 | 1.26 | 1.05-1.50 | 0.012 |
| ||||||
HDL Cholesterol | ||||||
| ||||||
66+ mg/dL | reference | reference | ||||
56 – 66 mg/dL | 1.04 | 0.90-1.21 | 0.60 | 1.02 | 0.86-1.20 | 0.86 |
50 - 56 mg/dL | 1.04 | 0.88-1.22 | 0.64 | 0.93 | 0.78-1.11 | 0.44 |
43 – 50 mg/dL | 1.00 | 0.85-1.17 | 0.98 | 0.83 | 0.70-1.00 | 0.05 |
< 43 mg/dL | 1.09 | 0.93-1.29 | 0.30 | 0.81 | 0.67-0.98 | 0.034 |
| ||||||
Total Cholesterol | ||||||
| ||||||
260+ mg/dL | reference | reference | ||||
236 – 259 mg/dL | 1.03 | 0.87-1.22 | 0.74 | 1.13 | 0.94-1.35 | 0.21 |
216 – 235 mg/dL | 1.12 | 0.95-1.32 | 0.17 | 1.20 | 1.00-1.44 | 0.05 |
195 - 215 mg/dL | 1.06 | 0.89-1.25 | 0.52 | 1.09 | 0.91-1.31 | 0.37 |
< 195 mg/dL | 1.18 | 1.00-1.39 | 0.05 | 1.14 | 0.95-1.36 | 0.17 |
| ||||||
Triglycerides | ||||||
| ||||||
185+ mg/dL | reference | reference | ||||
136 – 184 mg/dL | 0.94 | 0.80-1.10 | 0.44 | 0.97 | 0.81-1.15 | 0.70 |
106 – 135 mg/dL | 0.91 | 0.78-1.07 | 0.27 | 1.01 | 0.85-1.20 | 0.95 |
80 – 105 mg/dL | 0.93 | 0.79-1.09 | 0.37 | 1.05 | 0.88-1.26 | 0.56 |
< 80 mg/dL | 0.81 | 0.69-0.96 | 0.014 | 0.97 | 0.80-1.17 | 0.74 |
Adjusted for WHI trial arm, BMI, lipid-lowering medication, blood pressure, smoking status, coronary heart disease, stroke, peripheral artery disease, age, U.S. region, ethnicity, marital status, health insurance, alcohol consumption, leisure-time physical activity, cancer, income, education, diabetes, thyroid disease, and colitis